PASADENA, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24arwr&src=ctag” target=”_blank”gt;$arwrlt;/agt;–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to participate in the following upcoming events:
Bank of America Merrill Lynch 2019 Health Care Conference – Las
Vegas, May 14-16, 2019
May 15, 8:40 a.m. PDT – Christopher Anzalone, Ph.D., Arrowhead’s
president and chief executive officer, will deliver a corporate
presentation
Vascular Discovery: From Genes to Medicine 2019 Scientific Sessions
(ATVB|PVD) – Boston, May 14-16, 2019
May 15, 11:00 a.m. EDT – So Wong, Ph.D., Arrowhead’s director of
biology, will deliver a poster presentation titled, “Reduction in
Angiopoietin-Like Protein 3 via RNA Interference Improves Dyslipidemias
and Hepatic Steatosis”
2019 National Lipid Association Scientific Sessions – Aventura,
FL, May 16-19, 2019
May 18, 11:25 a.m. EDT – So Wong, Ph.D., Arrowhead’s director of
biology, will deliver a poster presentation titled, “Personalized
Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in
Apolipoprotein C3 or Angiopoietin-Like Protein 3”
20th Annual B. Riley FBR Institutional
Investor Conference – Beverly Hills, May 22-23, 2019
May 23, 8:30 a.m. PDT – Christopher Anzalone, Ph.D., Arrowhead’s
president and chief executive officer, will participate in a fireside
chat presentation with Mayank Mamtani, B. Riley FBR research analyst
A copy of the presentation materials and webcast links, if the
presentation is being webcast, may be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the likelihood and
timing of the receipt of future milestone and licensing fees, the future
success of our scientific studies, our ability to successfully develop
and commercialize drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation
to update or revise forward-looking statements to reflect new events or
circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
Contacts
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]
www.lifesciadvisors.com
